包装 | 价格(元) |
10mM (in 1mL DMSO) | 电议 |
20mg | 电议 |
100mg | 电议 |
Cell lines | Pyramidal neocortical cells |
Preparation method | Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 10 μM |
Applications | Gabapentin inhibited calcium currents in pyramidal neocortical cells (up to 34%). The gabapentin-mediated inhibition of calcium currents saturated at particularly low concentrations (around 10 μM), at least in neocortical neurons (IC50 about 4 microM) |
Animal models | Rat model of neuropathic pain dynamic allodynia, rat model of brain demyelination evoked by intracerebral injection (i.c.i) of ethidium bromide |
Dosage form | Oral administration, 10-100 mg/kg |
Application | In the rat model of neuropathic pain dynamic allodynia, gabapentin (10-100 mg/kg, p.o.) dose-dependently blocked both types of allodynia. The intrathecal administration of gabapentin dose-dependently (1-100 μg/animal) blocked both static and dynamic allodynia. Administration of similar doses of gabapentin into the hind paw failed to block these responses. In a rat model of brain demyelination evoked by intracerebral injection (i.c.i) of ethidium bromide, gabapentin administered at 300 mg/kg increased cortical MDA by 66%. Gabapentin decreased GPx activity by 54.3%. Gabapentin decreased nitrite by 21.4% and 29.2% at 100 and 300 mg/kg, respectively. Gabapentin increased AChE activity increased by 28.6% and 69.3% at 100 and 300 mg/kg, respectively. Gabapentin decreased paraoxonase activity by 83.3% and 73% at 100 and 300 mg/kg, respectively. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
文献引用 | |
产品描述 | Gabapentin (Neurontin) is a pharmaceutical drug, specifically a GABA analog. It was originally developed to treat epilepsy, and currently is also used to relieve neuropathic pain.IC50 Value: 140 nM (α2δ subunit of calcium channel) [1]Target: Calcium Channelin vitro: Gabapentin, baclofen and CGP 44532 all reduced the electrically stimulated release of [3H]glutamic acid (IC50=20 microM, 0.8 microM and 2 microM, respectively). Gabapentin was without effect on the release of [3H]GABA, whilst baclofen (IC50=8 microM) and CGP 44532 (IC50=1 microM) inhibited [3H]GABA release [2]. A large inhibition of calcium currents by gabapentin was observed in pyramidal neocortical cells (up to 34%). Significantly, the gabapentin-mediated inhibition of calcium currents saturated at particularly low concentrations (around 10 microM), at least in neocortical neurons (IC50 about 4 microM) [3].in vivo: Gabapentin produced an anti-allodynic effect over the 7-day period, reducing the expression of pro-inflammatory cytokines but increasing the expression of IL-10 (TNF-α, 316.0 ± 69.7 pg/mL vs 88.8 ± 24.4 pg/mL; IL-1β, 1,212.9 ± 104.5 vs 577.4 ± 97.1 pg/mL; IL-6, 254.0 ± 64.8 pg/mL vs 125.5 ± 44.1 pg/mL; IL-10, 532.1 ± 78.7 pg/mL vs 918.9 ± 63.1 pg/mL). The suppressive effect of gabapentin on pro-inflammatory cytokine expression was partially blocked by the anti-IL-10 antibody [4].Toxicity: No new safety signals or adverse event trends relating to GEn exposure were identified [5].Clinical trial: N/A References: |